The recently completed NCI-MATCH trial is one of the largest precision oncology studies undertaken to date, with 38 treatment arms. It is undoubtedly one of the first of its kind. The objective was to match genetic aberrations that drive tumor growth with available drugs targeting those aberrations, regardless of cancer type. Today, NCI-MATCH is having a profound and far-reaching impact across the field of oncology. 

In two new podcasts, Peter J. O'Dwyer, MD, group co-chair of the ECOG-ACRIN Cancer Research Group, shares his insights on the future of precision oncology based on NCI-MATCH results. Dr. O'Dwyer co-led the trial and is the first author of the recent Nature Medicine publication, The NCI-MATCH Trial: Lessons for Precision Oncology.¹

Cancer Trials Ireland Podcast

Professor Ray McDermott, clinical lead for Cancer Trials Ireland, interviews Dr. O'Dwyer about the NCI-MATCH results, how clinical trials have changed over time, the evolving area of genomic testing, why tumor sequencing should be considered for patients, and advancements for pancreatic cancer. Prof. McDermott is a member of the ECOG-ACRIN Principal Investigator Committee. Listen below.

HealthCast

In this episode, Dr. O'Dwyer and Lindsay N. Harris, MD, associate director of the National Cancer Institute's Cancer Diagnosis Program, discuss how precision oncology is expanding patient treatment options and increasing survival rates. They describe the new ComboMATCH initiative, which is the successor to NCI-MATCH, and they emphasize the importance of clinical trials for discovering better ways to treat cancer. Listen below.

^{1O’Dwyer PJ et al. The NCI-MATCH trial: lessons for precision oncology. Nat Med 29, 1349–1357 (2023). https://doi.org/10.1038/s41591-023-02379-4}